Why BeOne Medicines AG (ONC) stock moved
BeOne Medicines AG (ONC) shares climbed 6.4% to $374.08 as of October 15, 2026, a significant gain from the prior close of $351.48. BestStocks flagged the session as a major change for ONC. Below, we break down what changed for ONC, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ONC climbed 6.4% to $374.08
BeOne Medicines gained 5.73% to $371.62 after receiving a Zacks Rank #1 (Strong Buy) designation on October 15, 2026, accompanied by upward earnings revisions and analyst price-target increases from RBC Capital ($459), JPMorgan ($445), and Truist ($420), per Zacks. The Zacks Consensus Estimate for full-year earnings rose 15.2% over the prior 60 days. Volume of 302,713 shares ran 1.73x the intraday average, suggesting normal institutional participation. BeOne Medicines earnings scheduled for November 5, 2026; consensus EPS estimate $1.89.
What it means for BeOne Medicines AG investors
For BeOne Medicines AG investors, the balance of recent signals points to a bullish shift. On the constructive side: Strong 6.4% price move with conviction; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $402.89, implying +7.7% upside from $374.08. BestStocks rates the overall signal quality medium (66/100). With earnings roughly 21 days out, the next report is the most likely near-term test of the move.
ONC price reaction
ONC last traded at $374.08, up $22.60 (+6.43%) from the previous close of $351.48. The session traded on 1.9× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $346.50 and $374.08, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on BeOne Medicines AG (ONC)
The consensus analyst price target on BeOne Medicines AG (ONC) is $402.89, 7.7% above the recent $374.08. Over the past 90 days analysts logged 0 upgrades, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ONC line up.
The bullish case
- Wall Street's consensus price target of $402.89 implies +7.7% upside from $374.08.
- The Street's most bullish target is $459.00 (+22.7%).
- Strong 6.4% price move with conviction.
- Positive price momentum.
- BeOne Medicines AG (ONC) moved +2.53% from $350.15 to $359.00 on 2026-08-10, reaching a new 30-day high.
The bearish case
- The most bearish analyst target is $367.00 (-1.9%).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 15, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ONC
In-depth ONC event analyses
Frequently asked questions about ONC
Why did BeOne Medicines AG (ONC) stock move?
ONC climbed 6.4% to $374.08. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did ONC stock rise?
ONC gained 6.43% ($22.60) versus the prior close of $351.48, last trading at $374.08 on 1.9× average volume.
When is BeOne Medicines AG's next earnings date?
ONC's next earnings report is estimated for 2026-11-05 — about 21 days away.
What is the analyst price target for ONC?
The consensus analyst price target for ONC is $402.89, about 7.7% above the current $374.08. Over the past 90 days, analysts recorded 0 upgrades, 11 maintains, and 0 downgrades.
How BestStocks tracks ONC
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ONC-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for ONC, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 15, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.